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Abstract 
Background: Parkinson’s disease is a neurodegenerative disorder associated with oxidative stress and glutathione 
depletion. The induction of cellular glutathione levels by exogenous molecules is a promising neuroprotective 
approach to limit the oxidative damage that characterizes Parkinson’s disease pathophysiology. Dithiolethiones, a 
class of sulfur‑containing heterocyclic molecules, are known to increase cellular levels of glutathione; however, limited 
information is available regarding the influence of dithiolethione structure on activity. Herein, we report the design, 
synthesis, and pharmacological evaluation of a further series of dithiolethiones in the SH‑SY5Y neuroblastoma cell 
line.
Results: Our structure–activity relationships data show that dithiolethione electronic properties, given as Hammett 
σp constants, influence glutathione induction activity and compound toxicity. The most active glutathione inducer 
identified, 6a, dose‑dependently protected cells from 6‑hydroxydopamine toxicity. Furthermore, the protective 
effects of 6a were abrogated by the inhibitor of glutathione synthesis, buthionine sulfoximine, confirming the impor‑
tance of glutathione in the protective activities of 6a.
Conclusions: The results of this study further delineate the relationship between dithiolethione chemical structure 
and glutathione induction. The neuroprotective properties of analog 6a suggest a role for dithiolethiones as potential 
antiparkinsonian agents.
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Background
The incidences of neurodegenerative disorders are 
expected to greatly increase as the American population 
ages. Parkinson’s disease (PD), the second most common 
neurodegenerative disease, is a movement disorder char-
acterized by the gradual disintegration of the nigrostriatal 
dopaminergic pathway. The resulting depletions of stri-
atal dopamine (DA) give rise to the cardinal symptoms of 
the disease, including tremor, rigidity, bradykinesia, and 
postural instability. Additionally, cognitive issues, depres-
sion, and sleep disturbances are frequently observed 
non-motor symptoms. Although pharmacotherapeutic 
intervention is capable of providing symptomatic relief in 
PD, to date no therapy is able to arrest or reverse the pro-
gression of the disease.
The cause of PD is not currently fully understood; 
however, the etiology of sporadic PD, the most prevalent 
form of the disease, is probably multifactorial, involving 
a combination of genetic, environmental, and unknown 
factors. Increasingly, oxidative stress is emerging as a 
major player in neurodegenerative disorders such as 
PD. Analyses of the brains of PD patients have demon-
strated extensive cellular damage caused by oxidative 
stress [1]. Neurons may be particularly prone to oxida-
tive damage due to their high lipid content and oxy-
gen consumption. Dopaminergic neurons experience 
an additional oxidative burden due to the autoxidation 
and metabolism of DA. These processes yield damaging 
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electrophilic DA-quinones and reactive oxygen species 
(ROS). Additionally, many of the molecular hallmarks 
of PD, such as mitochondrial dysfunction, α-synuclein 
aggregation, neuroinflammation, increased monoamine 
oxidase B activity, and elevated levels of iron, are related 
to increased oxidative activity [2–7]. ROS cause lipid per-
oxidation, protein and DNA damage, and ultimately the 
demise of dopaminergic neurons [8–10] (Fig. 1).
As reactive oxygen species occur naturally in all cells, 
various antioxidants and enzymes have been evolved 
to mitigate their harmful effects. Glutathione (GSH), 
a cysteine-containing tripeptide, is the most abundant 
non-protein antioxidant in the body, and plays a crucial 
role in the detoxification of ROS and dopamine metab-
olites [11]. GSH can detoxify ROS non-enzymatically, 
forming oxidized glutathione (GSSG). GSH also serves 
as a cosubstrate for several phase II enzymes. Glu-
tathione S-transferase (GST) mediates the addition of 
GSH to electrophiles, such as dopamine o-quinone, and 
glutathione peroxidase (GPx) catalyzes the reduction of 
peroxides, including H2O2 [12, 13]. However, in PD, the 
oxidative load experienced by dopaminergic neurons 
overwhelms these endogenous cellular detoxification 
mechanisms. Indeed, postmortem analyses of the brains 
of PD patients have shown depleted levels of nigrostri-
atal GSH [14]. As such, increasing neuronal levels of GSH 
may provide therapeutic benefit against the damaging 
effects of oxidative stress in PD.
The rate-limiting step in the biosynthesis of GSH is 
mediated by glutamate cysteine ligase (GCL). Associated 
with the gene of this enzyme is the antioxidant response 
element (ARE), found in many genes that play a role in 
protecting cells from oxidative damage, including GCLC 
(the catalytic subunit of GCL), GST, GPx, NAD(P)
H:quinone oxidoreductase (NQO1), superoxide dis-
mutase, hemeoxygenase, catalase, and many others [15]. 
Stabilization and nuclear translocation of the transcrip-
tion factor Nrf2 (nuclear factor-erythroid-2 related fac-
tor-2) enhances the transcription of ARE-associated 
genes [16]. Nrf2 is a short-lived protein, undergoing rapid 
ubiquitination and proteasomal degradation under basal 
conditions, mediated by its repressor Keap1 (Kelch-like 
ECH-associated protein-1) [17–19]. Keap1 is a cysteine-
rich protein that serves as a sensor of oxidative and elec-
trophilic stress. The stabilization of Nrf2 is believed to 
involve modulation of some of the numerous cysteine 
residues of Keap1 by ROS and electrophiles, leading 
to enhanced Nrf2 stability and nuclear accumulation 
[20–22].
Dithiolethiones (DTTs) are a class of sulfur-containing 
heterocycles (Fig.  2). DTTs have been shown to induce 
the expression of a variety of ARE-associated detoxi-
fication enzymes and molecules, including GCLC and 
GSH, in numerous cell and tissue types; however, limited 
information is available regarding the activities of these 
interesting molecules in the CNS [23–25]. Our group is 
interested in exploring GSH induction as a potential neu-
roprotective strategy. In a previous report by our group, 
we described a preliminary SAR study of substituted 
DTTs as inducers of GSH in the SH-SY5Y neuroblastoma 
Fig. 1 Sources of oxidative stress in PD
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cell line (a dopaminergic cell line commonly employed in 
in vitro models of PD), with key findings that placement 
of electron withdrawing groups (EWGs) at the 4-posi-
tion and electron donating groups (EDGs) at the 5-posi-
tion induced the most glutathione [26–28]. Additionally, 
three of these GSH inducers demonstrated neuroprotec-
tion in the in vitro 6-hydroxydopamine (6-OHDA) model 
of neurotoxicity. Based on these initial findings, we 
sought to better understand the influence of DTT sub-
stituents on GSH induction. In this report, we describe 
the synthesis and GSH induction activities of additional 
substituted DTTs. The relationship between DTT struc-
ture and pharmacological activity is discussed.
Chemistry
A series of 4-, 5-, and 4, 5-disubstituted DTTs was syn-
thesized (Table  1) to determine the generality of the 
initial SAR findings previously communicated by us 
[26]. These molecules were designed to ensure that a 
diversity of electronic features were represented in the 
compounds evaluated, including various aryl, alkyl, and 
amino groups, with both electron donating and elec-
tron withdrawing properties. The syntheses of DTTs 
are shown in Scheme  1. Compounds 4a–c, 5a–d, and 
6b, g–i were synthesized from requisite β-keto esters 
by treatment with P4S10, S8, and (Me3Si)2O in refluxing 
toluene for 1–3  h in good to excellent yield [29]. Mol-
ecules 6d–e were synthesized from their correspond-
ing nitriles via reaction with NaH, S8, and CS2 in DMF 
at 0 °C for 30 min, in excellent yield [30]. Compound 6c 
was synthesized by refluxing 6a in acetic anhydride for 
30 min (Scheme 1). Molecules 6a and 6f were purchased 
commercially.
Fig. 2 Generalized structure of dithiolethiones
Table 1 Structures and Hammett sigma constants of DTTs
Entry R1 (σp) [31] R
2 (σp) [31] Entry
– H H D3T
1a 4‑NO2‑C6H4 (0.26) H (0) 4a
1b Ethyl (−0.15) H (0) 4b
1c CO2Et (0.50) H (0) 4c
2a H (0) Me (−0.17) 5a
2b H (0) 4‑F‑C6H4 (0.06) 5b
2c H (0) 4‑pyridinyl (0.44) 5c
2d H (0) 2‑furanyl (0.02) 5d
3a CO2Et (0.50) NH2 (−0.66) 6a
3b CO2Et (0.50) Me (−0.17) 6b
3c CO2Et (0.50) NHC(O)Me (0.00) 6c
3e 4‑Cl‑C6H4 (0.12) NH2 (−0.66) 6d
3d SO2Ph (0.68) NH2 (−0.66) 6e
3f CN (0.66) NH2 (−0.66) 6f
3g Cl (0.23) 4‑OMe‑C6H4 (−0.08) 6g
3h Cl (0.23) C6H5 (−0.01) 6h
3i Cl (0.23) Ethyl (−0.15) 6i
Scheme 1 Synthesis of dithiolethiones
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Results and discussion
DTTs were assayed for GSH induction. SH-SY5Y human 
neuroblastoma cells were treated with test compounds 
for 24  h at a concentration of 100  μM. The results are 
shown in Fig. 3 and are reported as a percentage of con-
trol. Among the four 5-substituted DTTs (5a–d) evalu-
ated, electron-donating 5-methyl substituted DTT 5a 
induced GSH to the highest extent (163 %) compared to 
the other 5-substituted DTTs evaluated. Compounds 5b, 
5c, and 5d, each containing electron-withdrawing aro-
matic groups, induced a lesser amount of GSH (94, 114 
and 130 %, respectively). These results are consistent with 
our previous findings that alkyl groups at this position 
are superior to aromatic groups.
Next evaluated were three 4-substituted molecules, 
4a–c, containing p-nitrophenyl, ethyl, and ester groups, 
respectively. Interestingly, electronically-different 4a 
and 4b increased GSH levels by almost the same extent 
(156  % for 4a, and 149  % for 4b). The activity of 4b is 
unexpected, as our previous work suggested that EDGs 
at this position would induce less GSH as their electron-
withdrawing counterparts. Surprisingly, when 4-ethyl 
ester substituted analog 4c was tested, significant toxicity 
was observed, and the GSH induction data for this com-
pound was omitted (vide infra).
Next, we explored the effects on GSH induction of 
substituting both the 4- and 5-positions of the DTT core 
with a variety of functional groups (compounds 6a–i). 
The most active molecule in this series was analog 6a 
(4-ethyl ester, 5-amino), which increased cellular GSH 
levels by 190  %. Interestingly, replacement of the pri-
mary amine of 6a with a methyl group, 6b, significantly 
reduced activity. Similarly, substitution of the ester of 6a 
with an aryl ring (6d) or chloro group (6g–i), diminished 
activity, regardless of the nature of the 5-position. The 
SAR data from disubstituted DTTs suggest that GSH 
induction is highest when the 4- and 5-positions pos-
sess strongly electron withdrawing and strongly electron 
donating groups, respectively. Compounds 6e (4-phenyl-
sulfonyl, 5-amino) and 6f (4-nitrile, 5- amino) exhibited 
toxicity when evaluated and the resulting GSH induction 
data were omitted (vide infra).
The above SAR data demonstrate that electronic 
parameters influence GSH induction activity. As such, we 
sought a method to quantitatively assess the electronic 
properties of substituted DTTs. We decided to explore 
Hammett’s σp constants (Table 1), which reflect the abil-
ity of substituted benzoic acids to stabilize a negatively 
charged carboxylate upon ionization of the correspond-
ing acid. The constants given for these ionizations are 
an indication of the release (−σp) or withdrawal (+σp) 
of electrons by a substituent, and provide an indication 
of the combined contributions of both inductive and 
resonance effects. We plotted our GSH induction val-
ues for 4- and 5-substituted compounds from this and 
our previous study (structures shown in Table 2) against 
reported Hammett σp constants (Fig.  4) [31]. As EDGs 
at the 5-position were observed to be beneficial to activ-
ity, we chose to use +σp for these types of functional 
groups, and −σp for EWGs, which appeared to impair 
GSH induction. Analogously, as EWGs generally had a 
positive influence on activity at the 4-position, we used 
+σp; −σp were employed for the less active EDGs. As 
can be seen in Fig. 4a, a linear relationship was observed 
between DTT electronic properties and GSH induction, 
with only two molecules, 4b and 5c, laying outside of the 
curve (r2 = 0.7969 with 4b and 5c omitted). Interested in 
whether electronics similarly influence activity for the 4, 
Fig. 3 DTT‑mediated GSH induction. SH‑SY5Y cells were treated with test compounds (100 μM) for 24 h, at which time total cellular GSH was meas‑
ured. Data shown are mean ± SEM of at least three different experiments. *P < 0.05
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5-disubstituted molecules, we summed the σp constants 
of both substituents (using the same approach to the sign 
of σp described above) and plotted these values with the 
respective GSH activity. Again, a relationship was seen, 
supporting the influence of electronic properties on GSH 
induction (r2 = 0.5383, Fig. 4b).
As previously mentioned, when DTTs 4c, 6e, and 6f 
were evaluated for GSH induction in SH-SY5Y cells, sig-
nificant toxicity was observed, and the GSH induction 
data for these molecules was omitted from the study. 
Interestingly, analogs 6a and 6b, amino and methyl 
5-substituted congeners of 4c, appeared to not be toxic 
to SH-SY5Y cells. Based on this observation, we began 
to suspect that DTT toxicity may be related to the value 
of σp at the 4-position. To test this hypothesis, we meas-
ured the viability of SH-SY5Y cells treated with our DTTs 
(100  µM, 24  h, Fig.  5). Molecules with 4-position σp 
constants ranging from −0.15 (4b) to 0.26 (4a) showed 
minimal toxicity to SH-SY5Y cells. However, when the σp 
constant was raised to 0.50 (4c), significant cell death was 
seen. Surprisingly, the addition of an amino or methyl 
substituent to the 5-position of 4c (compounds 6a and 
6b, respectively) appeared to restore viability. To confirm 
the beneficial effects on toxicity of an electron-donat-
ing group at the 5-position, the amino group of 6a was 
acylated, yielding 6c. As the σp constant of the acetamide 
group is 0.0, electron donation should not take place, 
and 6c would be expected to be toxic. This was indeed 
observed as shown by the restoration of toxicity of 6c. 
The beneficial effects of placing electron-donating sub-
stituents at the 5-position appears to be limited, however. 
When the σp constant of the 4-position of 6a (ethyl ester, 
σp = 0.50) was increased to 0.66 (nitrile, compound 6f), 
or 0.68 (sulfone, compound 6e), cell viability was once 
again decreased.
The above observation that GSH induction is depend-
ent on the magnitude of Hammett σp constants sug-
gests that DTTs substituents influence the reactivity of 
the dithiolethione ring. Stabilization of Nrf2 by DTTs 
is believed to result from alteration of the interaction 
between Nrf2 and its repressor, Keap1. In the presence 
of oxygen and cellular thiols, the DTTs D3T, oltipraz, 
and ADT generate superoxide anion, O2, a progenitor 
to H2O2 [32–34]. Either of these reactive oxygen species 
could oxidize the numerous sulfhydryl groups of Keap1, 
resulting in diminished ubiquitination and increased 
nuclear accumulation of Nrf2. The placement of sub-
stituents with larger σp constants on the dithiolethione 
ring may render the molecule more reactive to thiols, 
resulting in greater GSH induction. It is also likely that 
the toxicity observed by several of the evaluated DTTs 
may be a consequence of the above described mecha-
nism of action. The DTTs that were observed to be toxic 
to SH-SY5Y cells (4c, 6c, 6e and 6f) would be expected 
to induce more GSH than other evaluated DTTs, based 
on extrapolation of our GSH induction vs. σp plots. 
Given the current evidence for the proposed mechanism 
of action of Nrf2 activation by DTTs, it is possible that 
Table 2 DTT structures from  initial SAR study and  corre-
sponding Hammett sigma constants [26, 31]
R1 (σp) R
2 (σp) Entry
4‑OMe‑C6H4 (−0.08) H (0) 4d
C6H5 (−0.01) H (0) 4e
CH2CF3 (0.09) H (0) 4f
4‑Cl‑C6H4 (0.12) H (0) 4g
H (0) Ethyl (−0.15) 5e
H (0) Cyclopropyl (−0.21) 5f
H (0) 4‑Cl‑C6H4 (0.12) 5g
H (0) 4‑OMe‑C6H4 (−0.08) ADT
Fig. 4 GSH induction values of 4‑ and 5‑substituted DTTs (a), and 4, 5‑disubstituted DTTs (b) vs. Hammett σp constants
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toxicity results from an increased level of reactive oxygen 
species produced from DTTs with higher σp constants for 
the 4-position. Additional studies are currently planned 
to more clearly understand the nature of DTT toxicity.
The observed influence of DTT substituent σp con-
stants on GSH induction and compound toxicity has 
important implications in the design and selection of 
future molecules as neuroprotective agents. 4-Monosub-
stituted congeners must possess substituents with σp con-
stants that are less than 0.5 to avoid toxicity, thus limiting 
the extent of GSH induction possible. Their 5-monosub-
stituted counterparts must have strongly electron-donat-
ing groups to effect significant GSH induction; however, 
aliphatic groups, the most active function group at this 
position, were only able to increase GSH by a maximum 
of 165 % (compound 5a). Substitution of carbon-contain-
ing substituents at the 5-position with heteroatoms (O, 
N) would increase the electron donating effects at this 
site; however, efforts to synthesize such monosubstituted 
analogs proved to be problematic. Disubstituted DTT 6a 
appears to solve both of these issues: the strongly elec-
tron withdrawing ester at the 4-position, combined with 
the electron donating 5-amino group, provide the large 
values of σp needed for maximal GSH induction. Addi-
tionally, the 5-amino group mitigates the toxicity that is 
associated a large σp value for the 4-position. As the val-
ues of DTT substituents cannot be increased much more 
without causing toxicity, it is likely that the activity of 
analog 6a represents the upper limit of GSH induction 
for substituted DTTs.
Having identified a DTT that potently increases cellu-
lar GSH levels, we next evaluated the ability of 6a to pro-
tect against 6-OHDA induced toxicity, a commonly used 
neuroprotection model [35–38]. SH-SY5Y cells were pre-
treated with 6a for 24  h at concentrations of 6.25, 12.5, 
25, 50, and 100  μM, followed by concurrent exposure 
to 40 μM 6-OHDA for a further 24 h. Cell viability was 
then determined. As shown in Fig.  6 administration of 
40 µM 6-OHDA reduced cellular viability to 22 %. Excit-
ingly, pretreatment with 6a dose-dependently protected 
against the toxic effects of 6-OHDA. Protective effects 
were seen starting with a concentration of 12.5 µM (33 % 
viability), and plateaued with the doses of 50 and 100 µM; 
interestingly, these two doses were equally protective (56 
and 58 %, respectively).
The mechanism of 6-OHDA toxicity involves the gen-
eration of ROS and electrophilic quinone metabolites 
[39]. The increase in cellular GSH levels mediated by 6a 
likely protects against the oxidative insult of 6-OHDA. 
To explore the role that GSH plays in this protection, 
SH-SY5Y cells were co-treated with 6a and buthionine 
Fig. 5 Toxicity of DTTs. SH‑SY5Y cells were treated with the indicated molecules (100 μM) for 24 h, at which time viability was assessed. Data shown 
are mean ± SEM of at least three different experiments. *P < 0.05
Fig. 6 Neuroprotection of 6a against 6‑OH induced neurotoxicity. 
SH‑SY5Y cells were treated for 24 h with various concentrations of 6a, 
followed by co‑treatment with 6‑OHDA (40 μM) for a further 24 h, at 
which time cellular viability was assed. Data shown are mean ± SEM 
of at least three different experiments. *P < 0.05
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sulfoximine (BSO), an inhibitor of GCLC [40]. As shown 
in Fig. 7, administration of BSO (25 µM) was able to inhibit 
the ability of 6a (100 µM) to induce GSH, demonstrating 
that GSH induction is mediated through actions of GCLC. 
Additionally, the abrogation of GSH induction by BSO was 
able to block the neuroprotective effects of 6a (Fig. 8), con-
firming the importance of GSH in neuroprotection. DTTs 
are known, via stabilization of Nrf2, to induce the expres-
sion of numerous cytoprotective phase II enzymes, and it 
is possible that the activity of these enzymes contribute 
to the protective effects of 6a. However, as the protective 
effects of 6a can be blocked by inhibition of GSH induc-
tion, the contribution to neuroprotection of other phase II 
enzymes in this model may be minimal.
Many of the symptoms of PD arise as a result of deple-
tion of nigrostriatal DA levels. As such, current antiparkin-
sonian pharmacotherapeutic approaches are DA focused. 
These treatments aim to replace DA (levodopa), slow 
its metabolism (inhibitors of monoamine oxidase B and 
catecholamine O-methyltransferase), or supplement its 
effects (dopamine agonists). While these agents are able to 
provide symptomatic relief in PD, they do little to halt or 
reverse the progression of the disorder since they do not 
address the underlying oxidative damage that is responsi-
ble for the loss of dopaminergic neurons. The results of this 
study, while preliminary, suggest that elevation of cellular 
levels of GSH may have promise as a potential antioxidant-
based antiparkinsonian approach. Additional studies are 
currently planned to examine the neuroprotective poten-
tial of DTTs is additional cell lines and PD models.
Conclusions
In support of our effort to identify novel potential neu-
roprotective agents, a further series of substituted DTTs 
was synthesized and evaluated for GSH induction in the 
SH-SY5Y human neuroblastoma cell line. Our results 
showed that the extent of GSH induction is related to the 
electronic properties of DTTs. Plots of GSH induction vs. 
DTT substituent Hammett σp values demonstrated linear 
relationships for substituents of 4-, 5-, and 4, 5-disubsti-
tuted DTTs. It was also observed that the magnitude of 
σp at the 4-position influences DTT toxicity, which can 
be diminished by the presence of an EDG at the 5-posi-
tion. The most potent inducer of GSH identified in this 
study, congener 6a, was minimally toxic to cells and was 
able to provide neuroprotection in the 6-OHDA model 
of neurotoxicity, suggesting GSH induction as a neu-
roprotective strategy. GSH induction was shown to be 
crucial to neuroprotection, as the protective effects of 6a 
were abrogated by treatment with the GCLC inhibitor, 
BSO. The data generated in this study suggest that dithi-




All solvents and reagents obtained from commercial 
sources were used without further purification, unless 
otherwise noted. Compounds 6a and 6f were purchased 
from Oakwood Chemical (West Columbia, SC) and puri-
fied prior to use. All reactions were carried out under an 
argon atmosphere unless otherwise noted. All final mol-
ecules were  >95  % pure as judged by high-performance 
liquid chromatography (HLPC). HPLC analyses were 
performed on an Agilent 1220 Infinity system with an 
Agilent column (Poroshell 120 EC-C18, 4.6 ×  150  mm, 
gradient of 0.1 % trifluoroacetic acid/acetonitrile). 1H and 
13C NMR analyses were performed on a Varian Mercury 
Fig. 7 Suppression of GSH induction of 6a by BSO. SH‑SY5Y cells 
were treated with 6a (100 μM) and/or BSO (25 μM) for 24 h, at 
which time total cellular GSH levels were assessed. Data shown are 
mean ± SEM of at least three different experiments. *P < 0.05
Fig. 8 Abrogation of protective neuroprotective effects of 6a by BSO. 
SH‑SY5Y cells were treated with 6a (100 μM) and/or BSO (25 μM) for 
24 h, at which time either 6‑OHDA (40 μM) or DMSO was added. Cel‑
lular viability was measured 24 h later. Data shown are mean ± SEM 
of at least three different experiments. *P < 0.05
Page 8 of 11Brown et al. Chemistry Central Journal  (2016) 10:64 
300 MHz spectrophotometer at 300 and 75 MHz, respec-
tively. Chemical shifts are given in ppm in reference to 
tetramethylsilane (TMS) as an internal standard. Multi-
plicities are given as s (singlet), d (doublet), t (triplet), m 
(multiplet), and br s (broad signal). Low-resolution mass 
spectral data were obtained on an Agilent 1260 Infinity 
single quadrupole LCMS system. Melting points were 
taken on a Mel-Temp apparatus and are uncorrected. 
Thin layer chromatography (TLC) was performed on sil-
ica gel 60 F254-coated glass plates purchased from EMD 
Millipore, and visualized with UV light and/or basic 
KMnO4.
General procedure for the synthesis 
of dithiolethiones from β‑keto esters, exemplified 
by 5‑methyl‑3H‑1,2‑dithiole‑3‑thione, 5a [41]
To a suspension of elemental sulfur (123 mg, 3.85 mmol), 
phosphorus pentoxide (1.03 g, 2.31 mmol), hexamethyl-
disiloxane (2.76 mL, 11.6 mmol), in toluene (10 mL) was 
added β-oxo ester 2a (500 mg, 3.85 mmol). The mixture 
was heated under reflux conditions until complete as 
judged by TLC (generally between 1 and 3  h), at which 
time the reaction mixture was cooled to 0  °C. Saturated 
aqueous K2CO3 was added (5  mL) to destroy any unre-
acted phosphorus pentoxide. The crude product was then 
extracted with ethyl acetate (10 mL × 3), dried (Na2SO4), 
filtered, concentrated, and purified by column chroma-
tography (hexanes/ethyl acetate, 4:1) to give a low-melt-
ing red solid (521 mg, 91 %). Rf = 0.65 (20 % EtOAc/Hex). 
1H NMR (300 MHz, CDCl3): δ 2.52 (d, J = 0.99 Hz, 3 H), 
7.00–7.07 (m, 1 H). 13C NMR (75 MHz, CDCl3) δ: 18.43, 
139.41, 172.22, 216.66. Calc. 148, found 149 [M+H]+.
4‑(4‑Nitrophenyl)‑3H‑1,2‑dithiole‑3‑thione, 4a [42]
Prepared from 1a [43]. Red solid (92 %). Mp 152–154 °C. 
Rf = 0.37 (20 % EtOAc/Hex). 1H NMR (300 MHz, CDCl3): 
δ 7.89 (d, J = 8.73 Hz, 2 H), 8.30 (ds, J = 8.90 Hz, 2 H), 
9.34 (s, 1 H). 13C NMR (75  MHz, CDCl3): δ  =  128.67, 
135.59, 145.44, 151.15, 152.50, 166.47, 218.57. Calc. 255, 
found 256 [M+H]+.
4‑Ethyl‑3H‑1,2‑dithiole‑3‑thione, 4b [44]
Prepared from 1b [45]. Yellow oil (81 %). Rf = 0.46 (20 % 
EtOAc/Hex). 1H NMR (300  MHz, CDCl3): δ 1.15 (t, 
J = 7.43 Hz, 3 H), 2.48–2.73 (m, 2 H), 8.86 (t, J = 0.82 Hz, 
1 H). 13C NMR (75 MHz, CDCl3): δ 13.03, 23.52, 150.79, 
155.45, 215.12. Calc. 162, found 163 [M+H]+.
Ethyl 3‑thioxo‑3H‑1,2‑dithiole‑4‑carboxylate, 4c [46]
Prepared from diethyl 2-(ethoxymethylene)malonate, 1c. 
Red solid (47 %). Mp 61–62 °C. Rf = 0.48 (20 % EtOAc/
Hex). 1H NMR (300 MHz, CDCl3): δ 1.37 (t, J = 7.07 Hz, 
3 H), 4.35 (q, J = 7.19 Hz, 2 H), 9.18 (s, 1 H). 13C NMR 
(75 MHz, CDCl3): δ 14.35, 62.12, 138.30, 160.81, 165.22, 
211.31. Calc. 207, found 208 [M+H]+.
5‑(4‑Fluorophenyl)‑3H‑1,2‑dithiole‑3‑thione, 5b [47]
Red solid (74 %). Mp 98–100 °C. Rf = 0.84 (20 % EtOAc/
Hex). 1H NMR (300  MHz, CDCl3): δ 7.12–7.26 (m, 2 
H) 7.39 (s, 1 H) 7.59–7.72 (m, 2 H). 13C NMR (75 MHz, 
CDCl3): δ 116.97/117.26 (CF, d, J  =  22  Hz), 129.19, 
129.31, 136.13, 163.45/166.83 (CF, d, J = 254 Hz), 171.62, 
215.66. Calc. 228, found 229 [M+H]+.
5‑(Pyridin‑4‑yl)‑3H‑1,2‑dithiole‑3‑thione, 5c [48]
Red solid (34  %). Mp decomposed. Rf  =  0.09 (20  % 
EtOAc/Hex). 1H NMR (300 MHz, CDCl3): δ 7.50 (s, 1 H) 
7.52–7.59 (m, 2 H) 8.81 (d, J = 5.93 Hz, 2 H). 13C NMR 
(75 MHz, CDCl3): δ 121.02, 121.9, 145.67, 150.01, 175.25, 
214.27. Calc. 211, found 212 [M+H]+.
5‑(Furan‑2‑yl)‑3H‑1,2‑dithiole‑3‑thione, 5d [49]
Red solid (63 %). Mp 97–100 °C. Rf = 0.71 (20 % EtOAc/
Hex). 1H NMR (300 MHz, CDCl3): δ 6.61 (dd, J = 3.53, 
1.72 Hz, 1 H), 6.95–7.02 (m, 1 H), 7.38 (s, 1 H), 7.64 (dd, 
J =  1.81, 0.54  Hz, 1 H). 13C NMR (75  MHz, CDCl3): δ 
113.53, 113.59, 133.27, 146.60, 146.71, 160.27, 214.50. 
Calc. 200, found 201 [M+H]+.
Ethyl 5‑methyl‑3‑thioxo‑3H‑1,2‑dithiole‑4‑carboxylate, 6b 
[50]
Red solid (78 %). Mp 64–66 °C. Rf = 0.84 (20 % EtOAc/
Hex). 1H NMR (300 MHz, CDCl3): δ 1.37 (t, J = 7.16 Hz, 
3 H), 2.57 (s, 3 H), 4.39 (q, J = 7.07 Hz, 2 H). 13C NMR 
(75  MHz, CDCl3): δ 14.35, 19.11, 62.50, 140.80, 163.28, 
174.05, 211.82. Calc. 220, found 221 [M+H]+.
4‑Chloro‑5‑(4‑methoxyphenyl)‑3H‑1,2‑dithiole‑3‑thione, 
6g [51]
Prepared from 3g [52]. Yellow solid (91  %). Mp 125–
127 °C. Rf = 0.63 (20 % EtOAc/Hex). 1H NMR (300 MHz, 
CDCl3): δ 3.90 (s, 3 H), 7.07 (d, J = 9.06 Hz, 2 H), 7.67 (d, 
J = 9.06 Hz, 2 H). 13C NMR (75 MHz, CDCl3): δ 55.57, 
114.78, 124.12, 130.39, 123.43, 162.45, 165.62, 206.59. 
Calc. 274, found 275 [M+H]+.
4‑Chloro‑5‑phenyl‑3H‑1,2‑dithiole‑3‑thione, 6h [51]
Prepared from 3h   [53]. Yellow solid (87  %). Mp 105–
107 °C. Rf = 0.74 (2 % EtOAc/Hex). 1H NMR (300 MHz, 
CDCl3): δ 7.49–7.73 (m, 5 H). 13C NMR (75  MHz, 
CDCl3): δ 127.07, 128.88, 129.49, 129.79, 131.91, 165.63, 
206.88. Calc. 244, found 245 [M+H]+.
4‑Chloro‑5‑ethyl‑3H‑1,2‑dithiole‑3‑thione, 6i [54]
Prepared from 3i [55]. Yellow solid (59 %). Mp 83–84 °C. 
Rf  =  0.71 (20  % EtOAc/Hex). 1H NMR (300  MHz, 
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CDCl3): δ 1.40 (t, J = 7.52 Hz, 3 H), 2.98 (q, J = 7.61 Hz, 
2 H). 13C NMR (75 MHz, CDCl3): δ 12.80, 27.99, 158.84, 
171.46, 206.64. Calc. 196, found 197 [M+H]+.
Ethyl 5‑acetamido‑3‑thioxo‑3H‑1,2‑dithiole‑4‑carboxylate, 
6c [56]
Compound 6a (100 mg, 0.452 mmol) was refluxed in ace-
tic anhydride (5 mL) for 30 min. The solution was then 
cooled, concentrated to dryness, and the crude mate-
rial purified by column chromatography (hexanes/ethyl 
acetate, 3:1) to give 6c as a red solid (104  mg, 88  %). 
Mp 156–157  °C. Rf = 0.39 (20 % EtOAc/Hex). 1H NMR 
(300 MHz, CDCl3): δ 1.43 (t, J = 7.16 Hz, 3 H), 2.40 (s, 3 
H), 4.42 (q, J = 7.13 Hz, 2 H), 12.72 (br s, 1 H). 13C NMR 
(75  MHz, CDCl3): δ 14.15, 23.97, 62.68, 118.75, 166.36, 
170.63, 174.56, 208.25. Calc. 263, found 264 [M+H]+.
General procedure for the syntheses 
of dithiolethiones from nitriles, exemplified 
by 5‑amino‑4‑(4‑chlorophenyl)‑3H‑1,2‑dithiole‑3‑thione, 
6d
To an ice-cooled suspension of NaH (263  mg, 
6.58  mmol), carbon disulfide (220  μL, 3.62  mmol), and 
elemental sulfur (116  mg, 3.62  mmol) in DMF (5  mL) 
was added 3d (500 mg, 3.29 mmol) in DMF (1 mL). The 
mixture was allowed to stir at 0 °C for 30 min, at which 
time saturated Na2CO3 (10  mL) was added. The mix-
ture was then extracted with ethyl acetate (10 mL × 3), 
washed with water (10 mL × 3), dried (Na2SO4), filtered, 
concentrated, and purified by column chromatogra-
phy (hexanes/ethyl acetate 4:1) to yield 6d as a red solid 
(838 mg, 95 %). Mp 106–107 °C. Rf = 0.29 (20 % EtOAc/
Hex). 1H NMR (300  MHz, CDCl3): δ 6.35 (br s, 2 H), 
7.29 (d, J = 8.70 Hz, 2 H), 7.48 (d, J = 8.70 Hz, 1 H). 13C 
NMR (75 MHz, CDCl3): δ 130.00, 132.22, 132.27, 134.85, 
151.04, 175.69, 234.84. Calc. 259, found 260 [M+H]+.
5‑Amino‑4‑(phenylsulfonyl)‑3H‑1,2‑dithiole‑3‑thione, 6e 
[30]
Red solid (69 %). Mp decomposed. Rf = 0.13 (20 % EtOAc/
Hex). 1H NMR (300 MHz, CDCl3): δ 7.50–7.78 (m, 3 H), 
7.91–8.05 (m, 2 H), 9.01 (bs 1 H), 10.09 (bs, 1 H). 13C 
NMR (75 MHz, CDCl3): δ 117.75, 127.39, 128.77, 133.74, 
140.45, 180.23, 203.60. Calc. 289, found 290 [M+H]+.
Biological methods
Cell culture conditions
The SH-SY5Y human neuroblastoma cell line was 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). Cells were grown in DMEM:F-12 
media (1:1) supplemented with FBS (10 %) and 100 U/mL 
penicillin and 100  μg/mL streptomycin in 150  cm2 cul-
ture flasks in a humidified atmosphere of 5 % CO2. The 
media was replaced every 3–4 days, and cells were sub-
cultured once a confluence of 70–80 % was reached. All 
test compounds were dissolved in DMSO and diluted in 
media (final DMSO concentration of 0.1 % v/v).
Measurement of intracellular GSH levels
SH-SY5Y cells were seeded in white 96-well plates and 
allowed to adhere overnight. Media was removed and 
replaced with media containing either test compounds 
(100  μM) or DMSO (0.1  %) for 24  h. Total glutathione 
levels (GSH +  GSSG) were then measured using GSH/
GSSG Glo© assay from Promega (Madison, WI). GSH 
levels were expressed as a percentage of control.
Neuroprotection assay
SH-SY5Y cells were seeded in white 96 well plates and 
allowed to attach overnight. Media was removed and 
replaced with media containing either test compounds 
(100 μM) or DMSO for 24 h. Next, 6-OHDA (Aldrich) in 
media (final concentration of 40 μM) of media was added 
and the cells were co-treated for 24  h. Cellular viability 
was assessed using the CellTiter Glo© assay from Pro-
mega (Madison, WI). Viability was expressed as a per-
centage of control.
Statistical analyses
One-way analysis of variance (ANOVA) was used to test 
for significant differences using GraphPad Prism soft-
ware (La Jolla, CA). P values less than 0.05 were consid-
ered to be statistically significant. Results are expressed 
as mean ± SEM.
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